Strategies for pharmacotherapy of schizophrenia

Drugs of the Future

Volumn 33, Issue 9, 2008, Pages 777-791

  Arnt, J ^a   Bang Andersen, B ^a   Dias, R ^b   Bogeso K P ^a  

^a H LUNDBECK A S   (Denmark)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIFEPRUNOX; CIPROXIFAN; CLOZAPINE; DIHYDREXIDINE; DONEPEZIL; DOPAMINE 2 RECEPTOR STIMULATING AGENT; EPLIVANSERIN; FARAMPATOR; HALOPERIDOL; HISTAMINE H3 RECEPTOR ANTAGONIST; ISPRONICLINE; MP 10; MUSCARINIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OSANETANT; PF 2545920; PIMAVANSERIN; RISPERIDONE; SB 742457; SERTINDOLE; SONEPIPRAZOLE; TALNETANT; TANDOSPIRONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLINANSERIN; ZIPRASIDONE;

ALZHEIMER DISEASE; BLOOD PRESSURE; CLINICAL TRIAL; COGNITIVE DEFECT; DOPAMINE RECEPTOR BLOCKING; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FRONTAL CORTEX; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NEUROLOGIC DISEASE; NONHUMAN; NUCLEUS ACCUMBENS; ORTHOSTATIC HYPOTENSION; PATHOPHYSIOLOGY; PSYCHOPHARMACOTHERAPY; RECEPTOR AFFINITY; REVIEW; SCHIZOPHRENIA; SIDE EFFECT;

EID: 60749107251     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2008.033.09.1236966     Document Type: Review

References (137)

1. Saha, S., Chant, D., Welham, J., McGrath, J. A systematic review of the prevalence of schizophrenia. PLoS Med 2005, 2(5): e141.
2. Harrison, P.J., Weinberger, D.R. Schizophrenia genes, gene expression, and neuropathology: On the matter of their convergence. Mol Psychiatry 2005, 10(1): 40-68.
3. Green, M.F. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996, 153(3): 321-30.
4. Green, M.F., Kern, R.S., Heaton, R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: Implications for MATRICS. Schizophr Res 2004, 72(1): 41-51.
5. Harvey, P.D., Koren, D., Reichenberg, A., Bowie, C.R. Negative symptoms and cognitive deficits: What is the nature of their relationship? Schizophr Bull 2006, 32(2): 250-8.
6. Rodefer, J.S., Nguyen, T.N., Karlsson, J.J., Arnt, J. Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT(6) receptor antagonist: Comparison among antipsychotics. Neuropsychopharmacology 2008, 33(11): 2657-66.
7. Snigdha, S., Neill, J.C. Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats - A preliminary investigation. Behav Brain Res 2008, 187(2): 489-94.
8. Abdul-Monim, Z., Reynolds, G.P., Neill, J.C. The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behav Brain Res 2006, 169(2): 263-73.
9. Abdul-Monim, Z., Neill, J.C., Reynolds, G.P. Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. J Psychopharmacol 2007, 21(2): 198-205.
10. Grayson, B., Idris, N.F., Neill, J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 2007, 184(1): 31-8.
11. Goetghebeur, P., Dias, R. Comparison of haloperidol, risperidone, sertindole and modafinil to reverse an attentional set-shifting impairment following sub-chronic PCP administration in the rat - A back translational study. Psychopharmacology (Berl) 2008.
12. Horacek, J., Bubenikova-Valesova, V., Kopecek, M. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006, 20(5): 389-409.
13. Marino, M.J., Knutsen, L.J., Williams, M. Emerging opportunities for antipsychotic drug discovery in the postgenomic era. J Med Chem 2008, 51(5): 1077-107.
14. Spooren, W., Riemer, C., Meltzer, H. Opinion: NK3 receptor antagonists: The next generation of antipsychotics? Nat Rev Drug Discov 2005, 4(12): 967-75.
15. Patil, S.T., Zhang, L., Martenyi, F.V. et al. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: A randomized phase 2 clinical trial. Nat Med 2007, 13(9): 1102-7.
16. Schotte, A., Janssen, P.F., Gommeren, W. et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996, 124(1-2): 57-73.
17. Arnt, J., Skarsfeldt, T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 1998, 18(2): 63-101.
18. Roth, B.L., Sheffler, D.J., Kroeze, W.K. Magic shotguns versus magic bullets: Selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004, 3(4): 353-9.
19. Wong, E.H., Nikam, S.S., Shahid, M. Multi- and single-target agents for major psychiatric diseases: Therapeutic opportunities and challenges. Curr Opin Investig Drugs 2008, 9(1): 28-36.
20. Carpenter, W.T., Koenig, J.I. The evolution of drug development in schizophrenia: Past issues and future opportunities. Neuropsychopharmacology 2008, 33(9): 2061-79.
21. Laruelle, M., Kegeles, L.S., Abi-Dargham, A. Glutamate, dopamine, and schizophrenia: From pathophysiology to treatment. Ann N Y Acad Sci 2003, 1003: 138-58.
22. Abi-Dargham, A., Gil, R., Krystal, J. et al. Increased striatal dopamine transmission in schizophrenia: Confirmation in a second cohort. Am J Psychiatry 1998, 155(6): 761-7.
23. Egan, M.F., Goldberg, T.E., Kolachana, B.S. et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001, 98(12): 6917-22.
24. van Kammen, D.P., Boronow, J.J. Dextro-amphetamine diminishes negative symptoms in schizophrenia. Int Clin Psychopharmacol 1988, 3(2): 111-21.
25. Goldberg, T.E., Bigelow, L.B., Weinberger, D.R., Daniel, D.G., Kleinman, J.E. Cognitive and behavioral effects of the coadministration of dextroamphetamine and haloperidol in schizophrenia. Am J Psychiatry 1991, 148(1): 78-84.
26. Daniel, D.G., Weinberger, D.R., Jones, D.W. et al. The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia. J Neurosci 1991, 11(7): 1907-17.
27. Jentsch, J.D., Tran, A., Le, D., Youngren, K.D., Roth, R.H. Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neunopsychopharmacology 1997, 17(2): 92-9.
28. Moghaddam, B., Adams, B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281(5381): 1349-52.
29. Callicott, J.H., Bertolino, A., Mattay, V.S. et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000, 10(11): 1078-92.
30. Mattay, V.S., Goldberg, T.E., Fera, F. et al. Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine. Proc Natl Acad Sci USA 2003, 100(10): 6186-91.
31. Arvanov, V.L., Wang, R.Y. M100907, a selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate-receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro. Neuropsychopharmacology 1998, 18(3): 197-209.
32. Chen, G., Greengard, P., Yan, Z. Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proc Natl Acad Sci USA 2004, 101(8): 2596-600.
33. Marcus, M.M., Jardemark, K.E., Wadenberg, M.L., Langlois, X., Hertel, P., Svensson, T.H. Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat. Int J Neuropsychopharmacol 2005, 8(3): 315-27.
34. Li, Z., Bonhaus, D.W., Huang, M., Prus, A.J., Dai, J., Meltzer, H.Y. AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo [1,4]oxazin-3-one), a selective muscarinic M1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus. Eur J Pharmacol 2007, 572(2-3): 129-37.
35. Sur, C., Mallorga, P.J., Wittmann, M. et al. N-Desmethyl-clozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 2003, 100(23): 13674-9.
36. Goldman-Rakic, P.S., Castner, S.A., Svensson, T.H., Siever, L.J., Williams, G.V. Targeting the dopamine D1 receptor in schizophrenia: Insights for cognitive dysfunction. Psychopharmacology (Berl) 2004, 174(1): 3-16.
37. Newman-Tancredi, A., Cussac, D., Depoortere, R. Neuropharmacological profile of bifeprunox: Merits and limitations in comparison with other third-generation antipsychotics. Curr Opin Investig Drugs 2007, 8(7): 539-54.
38. Arnt, J., Hyttel, J. Dopamine D-2 agonists with high and low efficacies: Differentiation by behavioural techniques. J Neural Transm Gen Sect 1990, 80(1): 33-50.
39. Beaulieu, J.M., Gainetdinov, R.R., Caron, M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007, 28(4): 166-72.
40. Urban, J.D., Vargas, G.A., von Zastrow, M., Mailman, R.B. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways. Neuropsychopharmacology 2007, 32(1): 67-77.
41. Gray, J.A., Roth, B.L. The pipeline and future of drug development in schizophrenia. Mol Psychiatry 2007, 12(10): 904-22.
42. Shahid, M., Walker, G.B., Zorn, S.H., Wong, E.H. Asenapine: A novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2008.
43. Lieberman, J.A., Stroup, T.S., McEvoy, J.P. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353(12): 1209-23.
44. Rasmussen, K., Benvenga, M.J., Bymaster, F.P. et al. Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2- methyl-4H-3-thia-4,9-diazabenzo[f]azulene]: A potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. J Pharmacol Exp Ther 2005, 315(3): 1265-77.
45. Howard, H.R. 7-Phenylsulfonyl-tetrahydro-3-benzazepine derivatives as antipsychotic agents. Expert Opin Ther Pat 2005, 15(12): 1811-5.
46. Garzya, V., Forbes, I.T., Gribble, A.D. et al. Studies towards the identification of a new generation of atypical antipsychotic agents. Bioorg Med Chem Lett 2007, 17(2): 400-5.
47. Schmidt, C.J., Chapin, D.S., Cianfrogna, J. et al. Preclinical characterization of selective PDE10A inhibitors: A new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther 2008, 325(2): 681-90.
48. Menniti, F.S., Chappie, T.A., Humphrey, J.M., Schmidt, C.J. Phosphodiesterase 10A inhibitors: A novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007, 8(1): 54-9.
49. Rodefer, J.S., Murphy, E.R., Baxter, M.G. PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 2005, 21(4): 1070-6.
50. Kehler, J., Ritzén, A., Greve, D.R. The potential therapeutic use of phosphodiesterase 10 inhibitors. Expert Opin Ther Pat 2007, 17(2): 147-58.
51. Farampator. Recommended INN: List 54. WHO Drug Information 2005, 19(3). http://www.who.int/druginformation/vol19num3_2005/R-List54.pdf
52. Olsen, C.K., Kreilgaard, M., Didriksen, M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol Biochem Behav 2006, 84(2): 259-65.
53. Wezenberg, E., Verkes, R.J., Ruigt, G.S., Hulstijn, W., Sabbe, B.G. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology 2007, 32(6): 1272-83.
54. Arai, A.C., Kessler, M. Pharmacology of ampakine modulators: From AMPA receptors to synapses and behavior. Curr Drug Targets 2007, 8(5): 583-602.
55. Vabicaserin. Recommended INN: List 57. WHO Drug Information 2007, 21(1). http://www.who.int/druginformation/vol21num1_2007/R-List57.pdf
56. Rorick-Kehn, L.M., Johnson, B.G., Knitowski, K.M. et al. In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology (Berl) 2007, 193(1): 121-36.
57. Kuroki, T., Meltzer, H.Y., Ichikawa, J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 1999, 288(2): 774-81.
58. Ichikawa, J., Li, Z., Dai, J., Meltzer, H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT1A receptor agonism. Brain Res 2002, 956(2): 349-57.
59. Ichikawa, J., Dai, J., O'Laughlin, I.A., Fowler, W.L., Meltzer, H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 2002, 26(3): 325-39.
60. Bristow, L.J., Kramer, M.S., Kulagowski, J., Patel, S., Ragan, C.I., Seabrook, G.R. Schizophrenia and L-745,870, a novel dopamine D4 receptor antagonist. Trends Pharmacol Sci 1997, 18(6): 186-8.
61. Merchant, K.M., Gill, G.S., Harris, D.W. et al. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist. J Pharmacol Exp Ther 1996, 279(3): 1392-403.
62. Corrigan, M.H., Gallen, C.C., Bonura, M.L., Merchant, K.M. Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: A placebo-controlled trial. Biol Psychiatry 2004, 55(5): 445-51.
63. Arnsten, A.F., Murphy, B., Merchant, K. The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive deficits in monkeys. Neuropsychopharmacology 2000, 23(4): 405-10.
64. Jentsch, J.D., Taylor, J.R., Redmond, D.E. Jr., Elsworth, J.D., Youngren, K.D., Roth, R.H. Dopamine D4 receptor antagonist reversal of subchronic phencyclidine-induced object retrieval/detour deficits in monkeys. Psychopharmacology (Berl) 1999, 142(1): 78-84.
65. Kramer, M.S., Last, B., Getson, A., Reines, S.A. The effects of a selective D4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. D4 Dopamine Antagonist Group. Arch Gen Psychiatry 1997, 54(6): 567-72.
66. Floresco, S.B., Magyar, O., Ghods-Sharifi, S., Vexelman, C., Tse, M.T. Multiple dopamine receptor subtypes in the medial prefrontal cortex of the rat regulate set-shifting. Neuropsychopharmacology 2006, 31(2): 297-309.
67. Hertel, P., Didriksen, M., Pouzet, B. et al. Lu 35-138 ((+)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H- indol-3-yl)ethyl]-3,6-dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor: Characterisation of its in vitro profile and pre-clinical antipsychotic potential. Eur J Pharmacol 2007, 573(1-3): 148-60.
68. Millan, M.J., Mannoury la Cour, C., Novi, F. et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b- tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 2008, 324(2): 587-99.
69. Millan, M.J., Loiseau, F., Dekeyne, A. et al. S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. III. Actions in models of therapeutic activity and induction of side effects. J Pharmacol Exp Ther 2008, 324(3): 1212-26.
70. Millan, M.J., Gressier, H., Brocco, M. The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats. Eur J Pharmacol 1997, 321(3): R7-9.
71. Millan, M.J., Svenningsson, P., Ashby, C.R. Jr. et al. S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]- benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. II. A neurochemical, electrophysiological and behavioral characterization in vivo. J Pharmacol Exp Ther 2008, 324(2): 600-11.
72. Heidbreder, C.A., Gardner, E.L., Xi, Z.X. et al. The role of central dopamine D3 receptors in drug addiction: A review of pharmacological evidence. Brain Res Brain Res Rev 2005, 49(1): 77-105.
73. Cervo, L., Cocco, A., Petrella, C., Heidbreder, C.A. Selective antagonism at dopamine D3 receptors attenuates cocaine-seeking behaviour in the rat. Int J Neuropsychopharmacol 2007, 10(2): 167-81.
74. Salmi, P., Isacson, R., Kull, B. Dihydrexidine - The first full dopamine D1 receptor agonist. CNS Drug Rev 2004, 10(3): 230-42.
75. Mu, Q., Johnson, K., Morgan, P.S. et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007, 94(1-3): 332-41.
76. Meltzer, H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21(2, Suppl.): 106S-15S.
77. Meltzer, H.Y., Arvanitis, L., Bauer, D., Rein, W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 2004, 161(6): 975-84.
78. Talvik-Lotfi, M., Nyberg, S., Nordstrom, A.L. et al. High 5-HT2A receptor occupancy in M100907-treated schizophrenic patients. Psychopharmacology (Berl) 2000, 148(4): 400-3.
79. Wadenberg, M.G., Browning, J.L., Young, K.A., Hicks, P.B. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav 2001, 68(3): 363-70.
80. Li, Z., Ichikawa, J., Huang, M., Prus, A.J., Dai, J., Meltzer, H.Y. ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology (Berl) 2005, 183(2): 144-53.
81. Pimavanserin. Recommended INN: List 59. WHO Drug Information Prepublication copy 2008. http://www.who.int/drug-information/ vol21num4_2007/R-List59.pdf
82. Harvey, P.D., McClure, M.M. Pharmacological approaches to the management of cognitive dysfunction in schizophrenia. Drugs 2006, 66(11): 1465-73.
83. Keefe, R.S., Sweeney, J.A., Gu, H. et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison. Am J Psychiatry 2007, 164(7): 1061-71.
84. Keefe, R.S., Bilder, R.M., Davis, S.M. et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007, 64(6): 633-47.
85. 6 antagonists improve a subchronic phencyclidine-induced reversal learning deficit in rats. 1st SIRSC Conf (June 21-25, Venice) 2008.
86. Neill, J.C., Grayson, B., Idris, N.F., Witten, L.M., Brennum, L.T., Arnt, J. Sertindole improves a sub-chronic PCP-induced deficit in object recognition memory in the rat; comparison with risperidone. 1st SIRSC Conf (June 21-25, Venice) 2008.
87. McLean, S.L., Beck, J.P., Woolley, M.L., Neill, J.C. A preliminary investigation into the effects of antipsychotics on subchronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 2008, 189 (1): 152-8.
88. Wadenberg, M.L., Ahlenius, S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. J Neural Transm Gen Sect 1991, 83(1-2): 43-53.
89. Ichikawa, J., Meltzer, H.Y. R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)-sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum. J Pharmacol Exp Ther 1999I, 291(3): 1227-32.
90. Sumiyoshi, T., Matsui, M., Nohara, S. et al. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 2001, 158(10): 1722-5.
91. Ishizumi, K., Kojima, A., Antoku, F. Synthesis and anxiolytic activity of N-substituted cyclic imides (1R*,2S*,3R*,4S*)-N-[4-[4-(2-pyrimidinyl)-1- piperazinyl]butyl]-2,3-bicyclo-[2.2.1]heptanedicarboximide (tandospirone) and related compounds. Chem Pharm Bull (Tokyo) 1991, 39(9): 2288-300.
92. Barradell, L.B., Fitton, A. Tandospirone. CNS Drugs 1996, 5(2): 147-53.
93. Di Matteo, V., Di Giovanni, G., Di Mascio, M., Esposito, E. SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system. Neuropharmacology 1999, 38(8): 1195-205.
94. Rosenzweig-Lipson, S., Dunlop, J., Marquis, K.L. 5-HT2C receptor agonists as an innovative approach for psychiatric disorders. Drug News Perspect 2007, 20(9): 565-71.
95. Nasrallah, H.A. Atypical antipsychotic-induced metabolic side effects: Insights from receptor-binding profiles. Mol Psychiatry 2008, 13(1): 27-35.
96. Dunlop, J., Marquis, K.L., Lim, H.K. et al. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev 2006, 12(3-4): 167-77.
97. Li, Z., Huang, M., Prus, A.J., Dai, J., Meltzer, H.Y. 5-HT6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res 2007, 1134(1): 70-8.
98. Lacroix, L.P., Dawson, L.A., Hagan, J.J., Heidbreder, C.A. 5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex. Synapse 2004, 51(2): 158-64.
99. Dawson, L.A., Nguyen, H.Q., Li, P. The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. Neuropsychopharmacology 2001, 25(5): 662-8.
100. Hirst, W.D., Stean, T.O., Rogers, D.C. et al. SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. Eur J Pharmacol 2006, 553(1-3): 109-19.
101. Mitchell, E.S., Neumaier, J.F. 5-HT6 receptors: A novel target for cognitive enhancement. Pharmacol Ther 2005, 108(3): 320-33.
102. Didriksen, M., Skarsfeldt, T., Arnt, J. Reversal of PCP-induced learning and memory deficits in the Morris' water maze by sertindole and other antipsychotics. Psychopharmacology (Berl) 2007, 193(2): 225-33.
103. Leysen, J.E. Receptor profiles of antipsychotics. In: Atypical Antipsychotics. Ellenbroek, B.A., Cools, A.R. (Eds.). Birkhäuser Verlag, Basel, 2000, 57-81.
104. Gallhofer, B., Jaanson, P., Mittoux, A., Tanghoj, P., Lis, S., Krieger, S. Course of recovety of cognitive impairment in patients with schizophrenia: A randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 2007, 40(6): 275-86.
105. Pouzet, B., Didriksen, M., Arnt, J. Effects of the 5-HT(6) receptor antagonist, SB-271046, in animal models for schizophrenia. Pharmacol Biochem Behav 2002, 71(4): 635-43.
106. Linner, L., Wiker, C., Wadenberg, M.L., Schalling, M., Svensson, T.H. Noradrenaline reuptake inhibition enhances the antipsychotic-like effect of raclopride and potentiates D2-blockage-induced dopamine release in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2002, 27(5): 691-8.
107. Moltzen, E.K., Bang-Andersen, B. Serotonin reuptake inhibitors: The corner stone in treatment of depression for half a century - A medicinal chemistry survey. Curr Top Med Chem 2006, 6(17): 1801-23.
108. Jensen, N.H., Rodriguiz, R.M., Caron, M.G., Wetsel, W.C., Rothman, R.B., Roth, B.L. N-Desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT(1A) agonist, as a putative mediator of quetiapine's antidepressant activity. Neuropsychopharmacology 2008, 33(10): 2303-12.
109. Dabire, H. Idazoxan: A novel pharmacological tool for the study of alpha 2-adrenoceptors. J Pharmacol 1986, 17(2): 113-8.
110. Hertel, P., Fagerquist, M.V., Svensson, T.H. Enhanced cortical dopamine output and antipsychotic-like effects of raclopride by alpha2 adrenoceptor blockade. Science 1999, 286(5437): 105-7.
111. Litman, R.E., Su, T.P., Potter, W.Z., Hong, W.W., Pickar, D. Idazoxan and response to typical neuroleptics in treatment-resistant schizophrenia. Comparison with the atypical neuroleptic, clozapine. Br J Psychiatry 1996, 168(5): 571-9.
112. Wadenberg, M.L., Hertel, P., Fernholm, R., Hygge, B.K., Ahlenius, S., Svensson, T.H. Enhancement of antipsychotic-like effects by combined treatment with the alpha1-adrenoceptor antagonist prazosin and the dopamine D2 receptor antagonist raclopride in rats. J Neural Transm 2000, 107(10): 1229-38.
113. Casey, D.E. The relationship of pharmacology to side effects. J Clin Psychiatry 1997, 58(Suppl. 10): 55-62.
114. Jones, C.K., Brady, A.E., Bubser, M. et al. TBPB is a highly selective M1 allosteric muscarinic receptor agonist in vitro and produces robust antipsychotic-like effects in vivo. Neuropsychopharmacology 2006, 31(Suppl. 1): S116-7.
115. Shirey, J.K., Xiang, Z., Orton, D. et al. An allosteric potentiator of M4 mAChR modulates hippocampal synaptic transmission. Nat Chem Biol 2008, 4(1): 42-50.
116. Conn, P.J., Tamminga, C., Schoepp, D.D., Lindsley, C. Schizophrenia: Moving beyond monoamine antagonists. Mol Interv 2008, 8(2): 99-107.
117. Bymaster, F.P., Felder, C., Ahmed, S., McKinzie, D. Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 2002, 1(2): 163-81.
118. Lameh, J., Burstein, E.S., Taylor, E., Weiner, D.M., Vanover, K.E., Bonhaus, D.W. Pharmacology of N-desmethyl-clozapine. Pharmacol Ther 2007, 115(2): 223-31.
119. Arneric, S.P., Holladay, M., Williams, M. Neuronal nicotinic receptors: A perspective on two decades of drug discovery research. Biochem Pharmacol 2007, 74(8): 1092-101.
120. Bolognesi, M.L., Minarini, A., Tumiatti, V., Melchiorre, C. Progress in acetylcholinesterase inhibitors for Alzheimer's disease. Expert Opin Ther Pat 2006, 16(6): 811-23.
121. Keefe, R.S., Malhotra, A.K., Meltzer, H.Y. et al. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: Significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 2007, 33(6): 1217-28.
122. Esbenshade, T.A., Fox, G.B., Krueger, K.M. et al. Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl) benzonitrile]: I. Potent and selective histamine H3 receptor antagonist with drug-like properties. J Pharmacol Exp Ther 2005, 313(1): 165-75.
123. Medhurst, A.D., Atkins, A.R., Beresford, I.J. et al. GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer's disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther 2007, 321(3): 1032-45.
124. Fox, G.B., Esbenshade, T.A., Pan, J.B. et al. Selective H3 receptor (H3R) blockade: Broad efficacy in cognition and schizophrenia. Inflamm Res 2005, 54(Suppl. 1): S23-4.
125. Pillot, C., Ortiz, J., Heron, A., Ridray, S., Schwartz, J.C., Arrang, J.M. Ciproxifan, a histamine H3-receptor antagonist/inverse agonist, potentiates neurochemical and behavioral effects of haloperidol in the rat. J Neurosci 2002, 22(16): 7272-80.
126. Javitt, D.C. Glycine transport inhibitors and the treatment of schizophrenia. Biol Psychiatry 2008, 63(1): 6-8.
127. Konradsson, A., Marcus, M.M., Hertel, P., Svensson, T.H., Jardemark, K.E. Inhibition of the glycine transporter GlyT-1 potentiates the effect of risperidone, but not clozapine, on glutamatergic transmission in the rat medial prefrontal cortex. Synapse 2006, 60(2): 102-8.
128. Depoortere, R., Dargazanli, G., Estenne-Bouhtou, G. et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology 2005, 30(11): 1963-85.
129. Wolkenberg, S.E. Glycine transporter 1 (GlyT1) inhibitors for the treatment of schizophrenia. 236th ACS Natl Meet (Aug 17-21, Philadelphia) 2008, Abst MEDI 220.
130. Kinney, G.G., O'Brien, J.A., Lemaire, W. et al. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J Pharmacol Exp Ther 2005, 313(1): 199-206.
131. Harich, S., Gross, G., Bespalov, A. Stimulation of the metabotropic glutamate 2/3 receptor attenuates social novelty discrimination deficits induced by neonatal phencyclidine treatment. Psychopharmacology (Berl) 2007, 192(4): 511-9.
132. Karasawa, J., Hashimoto, K, Chaki, S. D-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 2008, 186(1): 78-83.
133. Andersen, J.D., Pouzet, B. Spatial memory deficits induced by perinatal treatment of rats with PCP and reversal effect of D-serine. Neuropsychopharmacology 2004, 29(6): 1080-90.
134. Johnson, S.A., Luu, N.T., Herbst, T.A. et al. Synergistic interactions between ampakines and antipsychotic drugs. J Pharmacol Exp Ther 1999, 289(1): 392-7.
135. Kinney, G.G., Sur, C., Burno, M. et al. The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J Neurosci 2003, 23(20): 7586-91.
136. Seeman, P. Glutamate agonists for schizophrenia stimulate dopamine D2High receptors. Schizophr Res 2008, 99(1-3): 373-4.
137. Heal, D.J., Smith, S.L., Fisas, A., Codony, X., Buschmann, H. Selective 5-HT6 receptor ligands: Progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 2008, 117(2):207-31.